Have your own idea? Try our Stock Screener
Argentinian (MERVAL) Healthcare Sector Analysis
UpdatedApr 30, 2026
DataAggregated Company Financials
Companies1
- 7D0.9%
- 3M-23.1%
- 1Y9.6%
- YTD-19.8%
The Healthcare industry has stayed flat over the last week. As for the the longer term, the industry is up 9.6% over the past 12 months.
Sector Valuation and Performance
Has the Argentinian Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 30 Apr 2026 | AR$132.8b | AR$126.7b | AR$2.4b | 53.7x | 55.3x | 1x |
| Sat, 28 Mar 2026 | AR$137.4b | AR$130.8b | -AR$1,946,644,487.00 | 54.7x | -70.6x | 1.1x |
| Mon, 23 Feb 2026 | AR$154.9b | AR$107.5b | -AR$10,024,883,532.00 | n/a | -15.5x | 1.4x |
| Wed, 21 Jan 2026 | AR$162.0b | AR$107.9b | -AR$10,105,872,344.00 | n/a | -16x | 1.5x |
| Fri, 19 Dec 2025 | AR$181.1b | AR$108.5b | -AR$8,970,776,885.00 | n/a | -20.2x | 1.7x |
| Sun, 16 Nov 2025 | AR$144.5b | AR$117.6b | -AR$6,282,831,000.00 | n/a | -23x | 1.2x |
| Tue, 14 Oct 2025 | AR$100.7b | AR$103.2b | AR$8.2b | 8.4x | 12.2x | 1x |
| Thu, 11 Sep 2025 | AR$95.7b | AR$104.5b | AR$9.0b | 7.6x | 10.6x | 0.9x |
| Sat, 09 Aug 2025 | AR$123.3b | AR$102.7b | AR$16.3b | 6x | 7.6x | 1.2x |
| Mon, 07 Jul 2025 | AR$116.6b | AR$104.7b | AR$17.4b | 5.9x | 6.7x | 1.1x |
| Wed, 04 Jun 2025 | AR$127.3b | AR$104.7b | AR$17.4b | 6.4x | 7.3x | 1.2x |
| Fri, 02 May 2025 | AR$121.7b | AR$100.1b | AR$22.4b | 4.9x | 5.4x | 1.2x |
| Sun, 30 Mar 2025 | AR$131.4b | AR$96.9b | AR$24.8b | 4.8x | 5.3x | 1.4x |
| Tue, 25 Feb 2025 | AR$129.5b | AR$42.6b | AR$18.2b | 6.4x | 7.1x | 3x |
| Thu, 23 Jan 2025 | AR$145.5b | AR$42.6b | AR$18.2b | 6.4x | 8x | 3.4x |
| Sat, 21 Dec 2024 | AR$142.4b | AR$42.6b | AR$18.2b | 6.7x | 7.8x | 3.3x |
| Mon, 18 Nov 2024 | AR$144.9b | AR$42.6b | AR$18.2b | 6.3x | 8x | 3.4x |
| Wed, 16 Oct 2024 | AR$83.2b | AR$40.7b | AR$4.6b | 13.2x | 18.3x | 2x |
| Fri, 13 Sep 2024 | AR$78.1b | AR$40.7b | AR$4.6b | 12.3x | 17.2x | 1.9x |
| Sun, 11 Aug 2024 | AR$81.4b | AR$41.1b | -AR$3,264,658,797.00 | 3.7x | -24.9x | 2x |
| Tue, 09 Jul 2024 | AR$84.4b | AR$41.1b | -AR$3,264,658,797.00 | 4.6x | -25.9x | 2.1x |
| Thu, 06 Jun 2024 | AR$85.3b | AR$41.1b | -AR$3,264,658,797.00 | 4.8x | -26.1x | 2.1x |
| Sat, 04 May 2024 | AR$75.6b | AR$43.6b | -AR$10,287,966,966.00 | 6.3x | -7.4x | 1.7x |
| Mon, 01 Apr 2024 | AR$73.6b | AR$9.6b | -AR$4,702,241,388.00 | 59.8x | -15.6x | 7.6x |
| Wed, 28 Feb 2024 | AR$75.5b | AR$9.6b | -AR$4,702,241,388.00 | 56.2x | -16x | 7.8x |
| Fri, 26 Jan 2024 | AR$88.6b | AR$10.3b | -AR$4,704,193,685.00 | 52.5x | -18.8x | 8.6x |
| Sun, 24 Dec 2023 | AR$64.1b | AR$10.3b | -AR$4,704,193,685.00 | 34.7x | -13.6x | 6.2x |
| Tue, 21 Nov 2023 | AR$52.8b | AR$13.0b | -AR$2,496,856,221.00 | n/a | -21.1x | 4x |
| Thu, 19 Oct 2023 | AR$53.0b | AR$13.0b | -AR$2,496,856,221.00 | n/a | -21.2x | 4.1x |
| Sat, 16 Sep 2023 | AR$44.9b | AR$18.8b | -AR$150,001,147.00 | 18.3x | -299.6x | 2.4x |
| Mon, 14 Aug 2023 | AR$45.4b | AR$18.8b | -AR$150,001,147.00 | 13.8x | -302.7x | 2.4x |
| Wed, 12 Jul 2023 | AR$41.4b | AR$18.8b | -AR$150,001,147.00 | 13.2x | -275.8x | 2.2x |
| Fri, 09 Jun 2023 | AR$42.5b | AR$19.1b | AR$209.1m | 136.4x | 203.2x | 2.2x |
| Sun, 07 May 2023 | AR$34.5b | AR$19.1b | AR$209.1m | 110.6x | 165.1x | 1.8x |
Price to Earnings Ratio
165.1x
Current Industry PE
- There is only one company in the Argentinean Healthcare industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have grown 126% per year over the last three years.
- Revenues for these companies have grown 88% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Argentinian Healthcare sector?
| AR Market | -0.39% | |
| Healthcare | 0.95% | |
| Pharma | 0.95% | |
Industry PE
- Investors are most optimistic about the Pharma industry which is trading above its 3-year average PE ratio.
- It looks like they are confident that earnings will grow faster in the future than they have historically.
- Investors are most pessimistic about the Pharma industry, although it looks like investor sentiment has improved given that it's trading above its 3-year average.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| RICH Laboratorios RichmondC.I.F | AR$1.60k | 0.9% +AR$1.2b | 9.6% | PE53.7x | |
| ROSE Instituto Rosenbusch | AR$167.00 | 1.2% +AR$85.2m | 88.3% | PS1.1x |